Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients

Ye Ji Kim, Youn Gon Lee, Dong Won Lee, Jae Hui Kim, Ye Ji Kim, Youn Gon Lee, Dong Won Lee, Jae Hui Kim

Abstract

Purpose: To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC).

Methods: Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration < 3 months) were included in this retrospective study. All patients underwent a single session of SRT with real-time feedback-controlled dosimetry. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) before and 3 months after treatment were examined and compared.

Results: The logarithm of minimal angle of resolution BCVA was significantly better 3 months after treatment (0.16 ± 0.18) than at the time of diagnosis (0.27 ± 0.18, P = 0.002). Additionally, subretinal fluid had resolved in all 16 eyes 3 months after treatment and CFT was significantly lower 3 months after treatment (215.6 ± 17.9 μm) than at baseline (441.4 ± 124.8 μm, P < 0.001). No notable SRT-related complications were observed during the study period.

Conclusion: The results of the present study suggest that SRT is a useful therapeutic option for patients with acute idiopathic CSC. Further studies are required to better understand the long-term efficacy of this treatment. This trial is registered with clinical trial registration number NCT03339856.

Figures

Figure 1
Figure 1
The laser pulse energy was emitted in a stepwise fashion (an increment of 3.57% for the following micropulse) for every individual spot. When there is an adequate feedback signal from the target retinal pigment epithelial (RPE) cells, the device stops the laser automatically during the 15-pulse set of a shot. If a shot was stopped at or between pulse numbers 4 and 15, the energy level would be deemed adequate for the shot and also adequate for the next shot. If the shot was stopped at earlier pulses, between pulse numbers 1 and 3, the shot's treatment was adequate for that spot by having received desired feedback from RPE, but for the next shot, the device recommends a decreased energy level to ensure the safety of the next shot. Conversely, if the desired feedback from a set of 15 pulses is not achieved, that is, no bubble is detected, then the energy level settings are too low. In this case, the device recommends incremental energy increases to achieve the desired feedback from RPE. ∗Up only if the laser was not stopped in 15 pulses.
Figure 2
Figure 2
A depiction showing the location of laser spots. Initially, a laser spot was applied to the leakage point (asterisk). Next, several additional laser spots were applied around the leakage point. The distance between the spots was generally set as 0.5 to 1.0 spot diameter (100 to 200 μm). Blue dotted circles indicate the location of laser spots. The numbers (1 to 5) indicate the order of laser spots.
Figure 3
Figure 3
Fundus photographs (a, e) as well as fluorescein angiographic (b) and optical coherence tomographic (OCT) (c, d, f–i) images of a 38-year-old patient with acute central serous chorioretinopathy treated with selective retina therapy (case number 5 in Tables 1 and 2). At diagnosis (a–d), best-corrected visual acuity (BCVA) was 20/25, and the patient complained of metamorphopsia. At the location of leakage, a shallow pigment epithelial detachment (PED) (d) (arrow) was observed adjacent to the pachy vessel (d) (asterisk). Three months after treatment (e–i), subretinal fluid had completely resolved and BCVA had improved to 20/20. A PED had resolved after treatment with thinning of the ellipsoid zone at the location of previous leakage (panel g, arrow). There was no notable treatment-related retinal pigment epithelial damage (f-g). The dotted circles in (b) indicate laser spots. Lowercase letters in panels (a) and (e) indicate OCT scanning lines for panels with the same letters.
Figure 4
Figure 4
Changes in best-corrected visual acuity (BCVA) (a) and central foveal thickness (b) after selective retinal therapy. There was a significant improvement in BCVA accompanied with significant decrease in central foveal thickness after treatment. Asterisks indicate significant difference when compared to the baseline value. logMAR: logarithm of minimal angle of resolution.

References

    1. Gass J. D. Pathogenesis of disciform detachment of the neuroepithelium: II. Idiopathic Central Serous Choroidopathy. American Journal of Ophthalmology. 63(3, Part 2):587–615.
    1. Hussain D., Gass J. D. Idiopathic central serous chorioretinopathy. Indian Journal of Ophthalmology. 1998;46(3):131–137.
    1. Gass J. D. Photocoagulation treatment of idiopathic central serous choroidopathy. Transactions Section on Ophthalmology American Academy of Ophthalmology and Otolaryngology. 1977;83, 3 Part 1:456–467.
    1. Taban M., Boyer D. S., Thomas E. L., Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. American Journal of Ophthalmology. 2004;137(6):1073–1080. doi: 10.1016/j.ajo.2004.01.043.
    1. Torres-Soriano M. E., Garcia-Aguirre G., Kon-Jara V., et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports) Graefe's Archive for Clinical and Experimental Ophthalmology. 2008;246(9):1235–1239. doi: 10.1007/s00417-008-0856-x.
    1. Roider J., Brinkmann R., Wirbelauer C., Laqua H., Birngruber R. Retinal sparing by selective retinal pigment epithelial photocoagulation. Archives of Ophthalmology. 1999;117(8):1028–1034. doi: 10.1001/archopht.117.8.1028.
    1. Elsner H., Pörksen E., Klatt C., et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2006;244(12):1638–1645. doi: 10.1007/s00417-006-0368-5.
    1. Framme C., Walter A., Berger L., et al. Selective retina therapy in acute and chronic-recurrent central serous chorioretinopathy. Ophthalmologica. 2015;234(4):177–188. doi: 10.1159/000439188.
    1. Klatt C., Saeger M., Oppermann T., et al. Selective retina therapy for acute central serous chorioretinopathy. The British Journal of Ophthalmology. 2010;95(1):83–88. doi: 10.1136/bjo.2009.178327.
    1. Park Y. G., Kang S., Kim M., Yoo N., Roh Y. J. Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients. Graefe's Archive for Clinical and Experimental Ophthalmology. 2017;255(7):1375–1383. doi: 10.1007/s00417-017-3672-3.
    1. Yasui A., Yamamoto M., Hirayama K., et al. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2017;255(2):243–254. doi: 10.1007/s00417-016-3441-8.
    1. Roider J., Brinkmann R., Wirbelauer C., Laqua H., Birngruber R. Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. The British Journal of Ophthalmology. 2000;84(1):40–47. doi: 10.1136/bjo.84.1.40.
    1. Turkcu F. M., Sahin A., Bez Y., et al. Vision-related quality of life in patients with chronic central serous chorioretinopathy. Seminars in Ophthalmology. 2013;30(4):272–275. doi: 10.3109/08820538.2013.839818.
    1. Sahin A., Bez Y., Kaya M. C., Türkcü F. M., Sahin M., Yüksel H. Psychological distress and poor quality of life in patients with central serous chorioretinopathy. Seminars in Ophthalmology. 2013;29(2):73–76. doi: 10.3109/08820538.2013.793728.
    1. Park Y. G., Seifert E., Roh Y. J., Theisen-Kunde D., Kang S., Brinkmann R. Tissue response of selective retina therapy by means of a feedback-controlled energy ramping mode. Clinical & Experimental Ophthalmology. 2014;42(9):846–855. doi: 10.1111/ceo.12342.
    1. Schuele G., Elsner H., Framme C., Roider J., Birngruber R., Brinkmann R. Optoacoustic real-time dosimetry for selective retina treatment. Journal of Biomedical Optics. 2005;10(6, article 064022) doi: 10.1117/1.2136327.
    1. Wallow I. H., Tso M. O. Repair after xenon arc photocoagulation. 2. A clinical and light microscopic study of the evolution of retinal lesions in the rhesus monkey. American Journal of Ophthalmology. 1973;75(4):610–626. doi: 10.1016/0002-9394(73)90813-1.
    1. Odrobina D., Laudanska-Olszewska I., Gozdek P., Maroszyński M., Amon M. Morphologic changes in the foveal photoreceptor layer before and after laser treatment in acute and chronic central serous chorioretinopathy documented in spectral-domain optical coherence tomography. Journal of Ophthalmology. 2013;2013:6.361513
    1. Daruich A., Matet A., Dirani A., et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research. 2015;48:82–118. doi: 10.1016/j.preteyeres.2015.05.003.
    1. Yannuzzi L. A., Slakter J. S., Gross N. E., et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–298. doi: 10.1097/00006982-200306000-00002.
    1. Reibaldi M., Cardascia N., Longo A., et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. American Journal of Ophthalmology. 2010;149(2):307–315.e2. doi: 10.1016/j.ajo.2009.08.026.
    1. Oiwa K., Kataoka K., Maruko R., Ueno S., Ito Y., Terasaki H. Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms. Japanese Journal of Ophthalmology. 2017;61(3):260–266. doi: 10.1007/s10384-017-0498-9.
    1. Aydin E. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. Journal of Ocular Pharmacology and Therapeutics. 2013;29(1):10–13. doi: 10.1089/jop.2012.0072.
    1. Shin K. H., Kim J. H., Cho S. W., Lee T. G., Kim C. G., Kim J. W. Efficacy of intravitreal bevacizumab for recurrent central serous chorioretinopathy in patients who had previously responded well to the same therapy. Journal of Ocular Pharmacology and Therapeutics. 2016;32(7):425–430. doi: 10.1089/jop.2015.0149.
    1. Bae S. H., Heo J., Kim C., et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology. 2014;121(2):558–565. doi: 10.1016/j.ophtha.2013.09.024.
    1. Chung Y. R., Seo E. J., Lew H. M., Lee K. H. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (London, England) 2013;27(12):1339–1346. doi: 10.1038/eye.2013.236.
    1. Lanzetta P., Furlan F., Morgante L., Veritti D., Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. European Journal of Ophthalmology. 2008;18(6):934–940.
    1. Chen S. N., Hwang J. F., Tseng L. F., Lin C. J. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–2234. doi: 10.1016/j.ophtha.2008.08.026.
    1. Herold T. R., Prause K., Wolf A., Mayer W. J., Ulbig M. W. Spironolactone in the treatment of central serous chorioretinopathy - a case series. Graefe's Archive for Clinical and Experimental Ophthalmology. 2014;252(12):1985–1991. doi: 10.1007/s00417-014-2780-6.
    1. Bousquet E., Beydoun T., Rothschild P. R., et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35(12):2505–2515. doi: 10.1097/IAE.0000000000000614.
    1. Brinkmann R., Roider J., Birngruber R. Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bulletin de la Société Belge d'Ophtalmologie. 2006;(302):51–69.
    1. Roider J., Hillenkamp F., Flotte T., Birngruber R. Microphotocoagulation: selective effects of repetitive short laser pulses. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(18):8643–8647. doi: 10.1073/pnas.90.18.8643.
    1. Brinkmann R., Huttmann G., Rogener J., Roider J., Birngruber R., Lin C. P. Origin of retinal pigment epithelium cell damage by pulsed laser irradiance in the nanosecond to microsecond time regimen. Lasers in Surgery and Medicine. 2000;27(5):451–464. doi: 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>;2-1.
    1. Schuele G., Rumohr M., Huettmann G., Brinkmann R. RPE damage thresholds and mechanisms for laser exposure in the microsecond-to-millisecond time regimen. Investigative Ophthalmology & Visual Science. 2005;46(2):714–719. doi: 10.1167/iovs.04-0136.
    1. Kitzmann A. S., Pulido J. S., Diehl N. N., Hodge D. O., Burke J. P. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008;115(1):169–173. doi: 10.1016/j.ophtha.2007.02.032.
    1. Tsai D. C., Chen S. J., Huang C. C., et al. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One. 2013;8(6, article e66858) doi: 10.1371/journal.pone.0066858.
    1. Fujimoto H., Gomi F., Wakabayashi T., Sawa M., Tsujikawa M., Tano Y. Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology. 2008;115(9):1494–1500.e2. doi: 10.1016/j.ophtha.2008.01.021.
    1. Gupta V., Gupta P., Dogra M. R., Gupta A. Spontaneous closure of retinal pigment epithelium microrip in the natural course of central serous chorioretinopathy. Eye. 2010;24(4):595–599. doi: 10.1038/eye.2009.193.
    1. Roberts P., Baumann B., Lammer J., et al. Retinal pigment epithelial features in central serous chorioretinopathy identified by polarization-sensitive optical coherence tomography. Investigative Ophthalmology & Visual Science. 2016;57(4):1595–1603. doi: 10.1167/iovs.15-18494.
    1. Wood E. H., Karth P. A., Sanislo S. R., Moshfeghi D. M., Palanker D. V. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina. 2017;37(6):1021–1033. doi: 10.1097/IAE.0000000000001386.

Source: PubMed

3
Abonnieren